Pharmaceutical

The International Society for Pharmaceutical Engineering has announced the 2020 Facility of the Year Awards category winners. The awards include:

VACUUBRAND is offering continuing education courses approved by the American Institute of Architects and Green Business Certification Inc. Providing engineers and designers with the skills to create sustainable, high-performance laboratories, each course is available as a general webinar, a private webinar, or as an on-demand learning experience. AIA members will receive one LU/HSW (Health-Safety-Welfare learning unit) for each one-hour course.

Federal financial measures have been approved in the past few weeks to shore up the economy during the COVID-19 pandemic, with direct monetary assistance and business loans totaling $5.5 trillion, and more support and flexibility for research universities and government contractors. The federal stimulus package—the Coronavirus Aid, Relief, and Economic Security (CARES) Act—is intended to pump $2.2 trillion dollars into the economy, primarily in the healthcare and research sectors, and to provide emergency relief to institutions, businesses, and workers whose livelihoods have been impacted by the pandemic. The specifics of how it will be implemented are still evolving, and it is likely that additional stimulus bills will be considered in the coming months, including investments in infrastructure for the nation’s research enterprise.

Regeneron Pharmaceuticals is constructing an $800 million manufacturing campus in East Greenbush, N.Y. The complex is now in the third and final phase of development, which includes an $188 million, 346,000-sf production facility; a 240,000-sf lab and office building; and a six-story, 1,050-space parking garage. BBL Construction Services is managing the project with completion expected by 2022.

A $2.2 trillion stimulus package will support the National Institutes of Health and the Centers for Disease Control and Prevention in their response to the SARS-CoV-2 pandemic. Funding from the Coronavirus Aid, Relief, and Economic Security Act (CARES) will be available to the agencies through September of 2024. The CDC will receive $4.3 billion in new funding, which includes $1.5 billion for joint initiatives with state and local governments. The NIH has been allocated $945.4 million, which will be directed to:

Vermeulens has released its market outlook report for the fourth quarter of 2019. Key points include:

Amicus Therapeutics opened the $25 million Global Research and Gene Therapy Center of Excellence in March of 2020 in Philadelphia. Accommodating up to 200 employees, the 75,000-sf project provides collaborative labs and offices to support the discovery and development of new therapies for rare metabolic diseases.

Audentes Therapeutics is planning to construct a $109 million gene therapy manufacturing facility in Sanford, N.C. The 135,000-sf project will support the production of genetic medicines based on adeno-associated virus vectors for the treatment of rare neuromuscular diseases. The center is expected to be operational by 2021. Audentes Therapeutics is a subsidiary of Astellas Pharma.

Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing.

The University of Iowa opened the $96.3 million College of Pharmacy in January of 2020 in Iowa City. Designed by OPN Architects and The S/L/A/M Collaborative, the 228,371-sf facility features a pharmacy practice simulation center, 23 instructional spaces, 16 flexible research labs, collaboration areas, and a 128-seat lecture hall for team-based learning. The structure stands six stories above grade, with a lower level housing two sterile production lines, a warehouse, and a vault to store controlled substances.

Merck KGaA broke ground in early 2020 on the $275 Biotech Development Center in Corsier-sur-Vevey, Switzerland. Constructed adjacent to the company's existing commercial manufacturing campus, the 169,000-sf project will provide advanced research, development, and production facilities to support the creation of innovative biological compounds for clinical studies.

Eli Lilly and Company opened the 11,500-sf Lilly Life Sciences Studio in San Diego in January of 2020. Part of a $90 million investment to expand the company's research footprint, the laboratory leverages a robotic cloud platform created by Strateos to enable other drug discovery companies and investigators to access the remote-controlled facility.

Eli Lilly & Company is planning to build a $474 million pharmaceutical manufacturing center in Durham, N.C. Located in Research Triangle Park, the next-generation facility will produce injectable therapeutics and delivery devices for conditions such as Type 2 diabetes. Accommodating over 450 new employees, the project will provide integrated manufacturing, engineering, and warehouse areas. Operations will commence at the site in 2023.

Foghorn Therapeutics broke ground in January of 2020 on its 60,000-sf headquarters in Cambridge, Mass. Located in Kendall Square, the facility will provide chemistry and biology labs, open offices, conference rooms, huddle rooms, and an employee café. Foghorn will occupy over three floors in the building, which is owned by Alexandria Real Estate Equities and managed by CBRE.

The National Institutes of Health is planning to build a dementia research center in Bethesda, Md. The 24,000-sf facility will provide labs, open collaboration spaces, conference rooms, and offices to support the discovery of new diagnostic tools and treatments for Alzheimer's disease and related conditions. The single-story structure will be delivered in less than two years using modular construction technologies. The cost of the project has yet to be determined, with estimates ranging from $25 to $100 million.